GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

Condition(s) studied

Investigational drug(s) / intervention(s)

GLP-1 receptor agonist: 2mg once weekly via subcutaneous injection

Study summary

Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials.

The presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a potential therapeutic target for prevention of cSVD progression and its disabling clinical outcomes. At the cellular and animal experimentation levels, GLP-1R agonist demonstrated reversal of some pathogenic processes in cSVD. However, its application to cSVD patients remains to be elucidated.

Investigator aims to investigate the safety and efficacy of GLP-1R agonist in patients with moderate-to-severe cSVD.

Eligibility

Primary outcome measure(s)

• Change of Brain Peak Width of Skeletonized Mean Diffusivity — Baseline and week 78
  Peak Width of Skeletonized Mean Diffusivity is a robust, fully-automated and easy-to-implement marker for cerebral small vessel disease based on diffusion tensor imaging, white matter tract skeletonization and histogram analysis. It is a biomarker for brain MRI images.

Trial sites (2)

More Chinese University of Hong Kong trials in China

Other trials for the same condition